Primary autoimmune neutropenia (pAN) is typified by onset in early infancy and a mild/ moderate phenotype that resolves within 3 years of diagnosis. In contrast, secondary AN is classically an adult disease associated with malignancy, autoimmunity, immunodeficiency, viral infection, or drugs. This study describes a cohort of 79 children from the Italian Registry who, although resembling pAN, did not fully match the criteria for pAN because neutropenia either appeared after age 5 years (LO-Np) or lasted longer than 3 years (LL-Np). These 2 categories compared with classical pAN showed a far inferior rate of resolution (P,.001), lower severity of neutropenia (P 5.03), leukopenia (P,.001), lymphopenia (P,.001) with low B1 (P 5.001), increased need of granulocyte colony-stimulating factor (P 5.04), and increased frequency of autoimmunity over the disease course (P,.001). A paired comparison between LO-Np and LL-Np suggested that LO-Np had a lower rate of resolution (P,.001) and lower white blood cell (P,.001) and lymphocyte (P,.001) values, higher occurrence of apthae (P 5.008), and a stronger association with autoimmune diseases/ markers (P 5.001) than LL-Np, thus suggesting a more pronounced autoimmune signature for LO-Np. A next-generation sequencing panel applied in a small subgroup of LO-Np and LL-Np patients identified variants related to immune dysregulations. Overall, these findings indicate that there are important differences among pAN LL-Np and LO-Np. Forms rising after 3 years of age, with low tendency to resolution, require tight monitoring and extensive immune investigations aimed to early identify underlying immunologic disease.

Late-onset and long-lasting autoimmune neutropenia: An analysis from the Italian Neutropenia Registry

Ramenghi U.;
2020-01-01

Abstract

Primary autoimmune neutropenia (pAN) is typified by onset in early infancy and a mild/ moderate phenotype that resolves within 3 years of diagnosis. In contrast, secondary AN is classically an adult disease associated with malignancy, autoimmunity, immunodeficiency, viral infection, or drugs. This study describes a cohort of 79 children from the Italian Registry who, although resembling pAN, did not fully match the criteria for pAN because neutropenia either appeared after age 5 years (LO-Np) or lasted longer than 3 years (LL-Np). These 2 categories compared with classical pAN showed a far inferior rate of resolution (P,.001), lower severity of neutropenia (P 5.03), leukopenia (P,.001), lymphopenia (P,.001) with low B1 (P 5.001), increased need of granulocyte colony-stimulating factor (P 5.04), and increased frequency of autoimmunity over the disease course (P,.001). A paired comparison between LO-Np and LL-Np suggested that LO-Np had a lower rate of resolution (P,.001) and lower white blood cell (P,.001) and lymphocyte (P,.001) values, higher occurrence of apthae (P 5.008), and a stronger association with autoimmune diseases/ markers (P 5.001) than LL-Np, thus suggesting a more pronounced autoimmune signature for LO-Np. A next-generation sequencing panel applied in a small subgroup of LO-Np and LL-Np patients identified variants related to immune dysregulations. Overall, these findings indicate that there are important differences among pAN LL-Np and LO-Np. Forms rising after 3 years of age, with low tendency to resolution, require tight monitoring and extensive immune investigations aimed to early identify underlying immunologic disease.
2020
4
22
5644
5649
https://ashpublications.org/bloodadvances/article/4/22/5644/474183/Late-onset-and-long-lasting-autoimmune-neutropenia
Adult; Child; Child, Preschool; Congenital Bone Marrow Failure Syndromes; Humans; Italy; Registries; Autoimmunity; Neutropenia
Fioredda F.; Rotulo G.A.; Farruggia P.; Dagliano F.; Pillon M.; Trizzino A.; Notarangelo L.; Luti L.; Lanza T.; Terranova P.; Lanciotti M.; Ceccherini I.; Grossi A.; Porretti L.; Verzegnassi F.; Mastrodicasa E.; Barone A.; Russo G.; Bonanomi S.; Boscarol G.; Finocchi A.; Veltroni M.; Ramenghi U.; Onofrillo D.; Martire B.; Ghilardi R.; Giordano P.; Ladogana S.; Marra N.; Zanardi S.; Beier F.; Miano M.; Dufour C.
File in questo prodotto:
File Dimensione Formato  
FioreddaBloodAd2021.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 764.8 kB
Formato Adobe PDF
764.8 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1846166
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 14
social impact